Metformina + Vildagliptina Aurovitas (Metformin Hydrochloride, Vildagliptin)

• Metformina + Vildagliptina combines metformin, a biguanide, with vildagliptin, a DPP‑4 inhibitor, to improve glycemic control in type 2 diabetes.
• Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used with diet and exercise.
• Adjunct therapy: provides additional glucose‑lowering effect when metformin alone is insufficient.
• Combination therapy: allows simultaneous targeting of hepatic glucose production and incretin‑mediated insulin secretion.

• Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while vildagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), prolonging the activity of endogenous incretin hormones (GLP‑1 and GIP). The combined actions increase insulin release in a glucose‑dependent manner and decrease glucagon secretion, resulting in improved overall glycemic control.

Metformina + Vildagliptina is associated with several adverse reactions that vary in frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Headache: mild to moderate intensity.
• Hypoglycemia: especially when combined with insulin or sulfonylureas.
• Upper respiratory tract infection: mild symptoms.
• Dizziness: transient episodes.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic complication.
• Severe hypoglycemia: prolonged low blood glucose requiring medical intervention.
• Pancreatitis: acute inflammation of the pancreas.
• Hepatic dysfunction: elevated liver enzymes or hepatic failure.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Renal impairment: worsening kidney function in susceptible patients.

• Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.
• Renal function: assess baseline creatinine clearance and adjust therapy as needed.
• Hepatic function: monitor liver enzymes because metformin‑associated lactic acidosis risk increases with hepatic impairment.
• Cardiovascular status: avoid in patients with unstable heart failure or severe hypoxia.
• Concomitant hypoglycemics: adjust doses of insulin or sulfonylureas to reduce hypoglycemia risk.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep below 25 °C, in the original packaging, and protect from moisture.

Metformina + Vildagliptina may interact with several medicines, requiring caution or avoidance.

Major Interactions (Avoid)

• Sulfonylureas or insulin: increased risk of severe hypoglycemia.
• Iodinated contrast agents: potential for metformin‑associated lactic acidosis.
• Cimetidine: may raise metformin plasma concentrations.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate vildagliptin exposure.
• Excessive alcohol: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal clearance of metformin.
• ACE inhibitors/ARBs: monitor renal function and electrolytes.
• Beta‑blockers: can mask hypoglycemia symptoms.
• Thyroid hormones: may alter glucose metabolism.
• Rifampin: may reduce vildagliptin plasma levels, decreasing efficacy.